… malignancies; and oral VNR for non–small cell lung cancer (NSCLC). With … High-dose
celecoxib and metronomic “Low-dose” … chemotherapy combined with bevacizumab and erlotinib in …

… In advanced non-small cell lung cancer (NSCLC) patients … clinical trial of stage III colon
cancer, additional celecoxib to … Combined use of celecoxib and erlotinib (EGFR inhibitor) also …

… on non-small cell lung cancer (NSCLC) and gastric cancer is … First is Cyclooxygenase-2(COX-2)
inhibitor Celecoxib. COX-… to assess the efficacy of fruquintinib in combination with other …

… advanced non-small-cell lung cancer. The results of this … Erlotinib combined with gemcitabine
is the first-line treatment … In a phase II study, 800 mg/day of celecoxib combined with …

… of the trial is to recommend the BOD of several doses of celecoxib combined with
erlotinib at a fixed dose in patients diagnosed with advanced non-small-cell lung cancer (NSCLC). …

… For Erlotinib, several phase I and phase II studies have … A phase II study of celecoxib in
combination with paclitaxel, … with inoperable stage IIIA/B nonsmall cell lung cancer. Clin …

… with a well-established safety profile and optimal dosing. Statins are inhibitors of HMG-CoA …
in non-small cell lung carcinoma treated with inhibitors; gefitinib and erlotinib because of …

… intermittent dosing, weekly dosing, or a combination of agents. If … The combination of erlotinib
and celecoxib led to 63% … This makes it more difficult to determine whether the combination …

… toxic at lower doses and efficient alone or in combination for a … consistency) of biological
systems, together with the varying … the therapeutic window is essential to ascertain the benefits …

… cancer (HRPC) cell lines [Citation82] and non-small-cell … of YM155 in combination with the
tyrosine kinase inhibitor erlotinib in … with IL-2, cyclophosphamide and the NSAID celecoxib to …